作者:Simone Schierle、Cathrin Flauaus、Pascal Heitel、Sabine Willems、Jurema Schmidt、Astrid Kaiser、Lilia Weizel、Tamara Goebel、Astrid S. Kahnt、Gerd Geisslinger、Dieter Steinhilber、Mario Wurglics、G. Enrico Rovati、Achim Schmidtko、Ewgenij Proschak、Daniel Merk
DOI:10.1021/acs.jmedchem.8b00458
日期:2018.7.12
bioactive small molecules with potentially superior efficacy and safety. Particularly multifactorial chronic inflammatory diseases demand multiple pharmacological interventions for stable treatment. By minor structural changes, we have developed a close analogue of the cysteinyl-leukotriene receptor antagonist zafirlukast that simultaneously inhibits soluble epoxide hydrolase and activates peroxisome p
多靶点设计可提供具有潜在优势的功效和安全性的生物活性小分子。特别是多因素慢性炎症性疾病,需要多种药理干预措施才能稳定治疗。通过微小的结构变化,我们开发了半胱氨酰-白三烯受体拮抗剂扎鲁司特的紧密类似物,其同时抑制可溶性环氧化物水解酶并激活过氧化物酶体增殖物激活的受体γ。三重调节剂在体内表现出强大的抗炎活性,并突出了设计的多靶点药物的治疗潜力。